Are CAR T-cell therapies safe for patients with impaired renal function?

The Multiple Myeloma Hub was pleased to speak to Surbhi Sidana, Stanford Medicine, Stanford, US. We asked, Are chimeric antigen receptor (CAR) T-cell therapies safe for patients with impaired renal function?

In this interview, Sidana opens by noting the lack of inclusion of patients with impaired renal function in the pivotal CAR T clinical trials. Sidana goes on to discuss data collected by the US Myeloma CAR T Consortium, assessing the efficacy and safety of the use of CAR T-cell therapies in real-world to treat patients with renal impairment. The outcomes in these patients following CAR T-cell therapy are discussed in terms of response, progression-free survival, non-relapse mortality, and safety outcomes including cytokine release syndrome and infection rates.